CoV-2 S1 (319-541), Sf9
Sf9, Baculovirus cells.
Severe acute respiratory syndrome coronavirus 2, COVID-19, COVID-19 virus, COVID19, HCoV-19, Human coronavirus 2019, SARS-2, SARS-CoV2, SARS2, Wuhan coronavirus, Wuhan seafood market pneumonia virus, SARS-CoV-2 SP RBD, 2019-nCoV SP RBD, 2019-nCoV, 2019-nCoV; Spike RBD Protein.
Greater than 95.0% as determined by SDS-PAGE.
Description
Recombinant Coronavirus 2019-nCoV Spike Glycoprotein-S1 Receptor Binding Domain is a single, glycosylated polypeptide chain containing a total of 232 amino acids (319-541) and having a calculated Mw of 26.2 kDa.
CoV-2 S1 (319-541) is fused to a 6 amino acid His-tag at C-terminus,and is purified by proprietary chromatographic techniques.
Product Specs
The 2019 novel coronavirus (2019-nCoV), a human-infecting coronavirus causing viral pneumonia, emerged in a Wuhan, Hubei province, China fish market in December 2019. This virus, 87% identical to the 2018 SARS-CoV-2 bat coronavirus found in Zhoushan, eastern China, likely shares a similar receptor-binding domain (RBD) structure despite some differences. This suggests 2019-nCoV may bind to the human ACE2 (angiotensin-converting enzyme 2) receptor. While bats are considered the likely origin, researchers believe an intermediary animal at the seafood market facilitated human transmission. Notably, RSCU analysis indicates 2019-nCoV's spike glycoprotein could be a recombinant of bat coronavirus and an unidentified coronavirus.
This product consists of a single, glycosylated polypeptide chain representing the Receptor Binding Domain (RBD) of the SARS-CoV-2 Spike Glycoprotein-S1. It encompasses amino acids 319-541, resulting in a molecular weight of 26.2 kDa.
A 6 amino acid His-tag is fused to the C-terminus of the CoV-2 S1 (319-541). Purification is achieved using proprietary chromatographic techniques.
The provided CoV-2 S1 (319-541) solution has a concentration of 0.25mg/ml. It is prepared in a Phosphate-Buffered Saline (pH 7.4) solution containing 10% glycerol.
For optimal storage, keep the product refrigerated at 4°C if you plan to use the entire vial within 2-4 weeks. For longer storage periods, freezing at -20°C is recommended. Consider adding a carrier protein like 0.1% HSA or BSA for extended storage. Minimize freeze-thaw cycles to maintain product integrity.
Analysis using SDS-PAGE confirms a purity greater than 95.0%.
The product's biological activity is evaluated based on its binding affinity to Human ACE-2 in a functional ELISA assay (refer to CAT# enz-1159).
Severe acute respiratory syndrome coronavirus 2, COVID-19, COVID-19 virus, COVID19, HCoV-19, Human coronavirus 2019, SARS-2, SARS-CoV2, SARS2, Wuhan coronavirus, Wuhan seafood market pneumonia virus, SARS-CoV-2 SP RBD, 2019-nCoV SP RBD, 2019-nCoV, 2019-nCoV; Spike RBD Protein.
Sf9, Baculovirus cells.
ADPRVQPTES IVRFPNITNL CPFGEVFNAT RFASVYAWNR KRISNCVADY SVLYNSASFS TFKCYGVSPT KLNDLCFTNV YADSFVIRGD EVRQIAPGQT GKIADYNYKL PDDFTGCVIA WNSNNLDSKV GGNYNYLYRL FRKSNLKPFE RDISTEIYQA GSTPCNGVEG FNCYFPLQSY GFQPTNGVGY QPYRVVVLSF ELLHAPATVC GPKKSTNLVK NKCVNFHHHH HH
Product Science Overview
The Coronavirus 2019-nCoV, also known as SARS-CoV-2, is the virus responsible for the COVID-19 pandemic. One of the critical components of this virus is the spike (S) glycoprotein, which plays a crucial role in the virus’s ability to infect host cells. The spike glycoprotein is composed of two subunits, S1 and S2. The S1 subunit contains the receptor-binding domain (RBD), which is responsible for binding to the host cell receptor, angiotensin-converting enzyme 2 (ACE2). The recombinant form of this protein, expressed in SF9 insect cells, is used extensively in research and vaccine development.
The spike glycoprotein of SARS-CoV-2 is a large type I transmembrane protein that protrudes from the viral envelope. It is responsible for mediating the entry of the virus into host cells. The S1 subunit of the spike protein contains the receptor-binding domain (RBD), which directly interacts with the ACE2 receptor on the surface of host cells . This interaction is the first step in the viral entry process, leading to the fusion of the viral and cellular membranes.
The spike protein is heavily glycosylated, with numerous N-linked glycans that play roles in protein folding, stability, and immune evasion . The glycosylation patterns can also affect the antigenicity of the spike protein, influencing the immune response.
The recombinant form of the SARS-CoV-2 spike glycoprotein S1 receptor-binding domain is often produced using the baculovirus expression system in SF9 insect cells. This system is advantageous due to its ability to produce large quantities of protein with post-translational modifications similar to those in mammalian cells . The recombinant protein can be used for various applications, including structural studies, vaccine development, and serological assays.
The recombinant spike glycoprotein S1 RBD is a critical tool in the development of vaccines and therapeutic antibodies. By studying the structure and function of the RBD, researchers can design vaccines that elicit strong neutralizing antibody responses . Additionally, the recombinant protein can be used in serological assays to detect antibodies in individuals who have been exposed to the virus or vaccinated.
